Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company headquartered in Aliso Viejo, California, focused on therapies for glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and markets the iStent family of micro-bypass stents. Its growth engine today centers on iDose TR, a long-duration intracameral implant that delivers continuous glaucoma medication inside the eye, and Epioxa, the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus. Glaukos sells to ambulatory surgery centers, hospitals, and physician practices through a direct sales organization and distributors. I follow the stock for its leadership in procedural ophthalmic innovation and its expanding product pipeline, and I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, GKOS climbed from a closing price of approximately $167.89 to $245.72, a gain of about 46%. The advance was concentrated around the company's October 28 earnings release, when shares jumped more than 30% in a single session and reached a 52-week high of $248.75 on October 30. The move was accompanied by unusually heavy trading volume, signaling broad institutional and retail participation. From roughly $184.53 about three months earlier, the stock has risen approximately 33%, extending a year-to-date rally of more than 100% off a 52-week low of $83.78. The multi-month advance reflects sustained commercial momentum in iDose TR and the early-stage launch of Epioxa, rather than a single isolated catalyst.
The primary catalyst was Glaukos' third-quarter 2026 earnings report, released October 28. The company posted record net sales of $211.0 million, up 58% year over year and well ahead of analyst expectations near $168 million. Non-GAAP earnings per share reached $0.47, versus a consensus estimate that anticipated a loss, while GAAP net income turned positive at $2.0 million compared with a $16.2 million net loss a year earlier. Growth was led by two products. iDose TR generated approximately $76 million in quarterly sales, helping drive U.S. glaucoma revenue up 47% to $118.6 million. Epioxa contributed roughly $53 million in its first full quarter following the establishment of its product-specific J-code, lifting corneal health revenue 154% to $59 million. Non-GAAP gross margin expanded nearly 400 basis points to about 88% on a favorable product mix. Investors reacted most strongly to forward guidance. Management raised full-year 2026 revenue guidance to $775 million–$785 million from $680 million–$700 million and introduced a preliminary 2027 revenue target of $1 billion. Analysts responded by reiterating Buy ratings, with Truist setting a $255 price target, Needham a $251 target, and Citi a $247 target. The company also reported positive Phase IV data for iDose TR used in combination with cataract surgery, reinforcing the therapy's clinical differentiation.
The broader three-month advance reflects a fundamental inflection rather than a short-term trading event. Across the quarter, Glaukos demonstrated accelerating adoption of iDose TR, which continues to expand its trained-surgeon base and market access, and made meaningful progress on the commercial launch of Epioxa. The company also launched its "Could it be KC?" keratoconus awareness campaign in partnership with NBA champion Stephen Curry, aimed at earlier disease detection and diagnosis. The quarter also featured continued expansion of the company's clinical pipeline, which spans more than a dozen disclosed programs across corneal, glaucoma, and retinal platforms. A lingering overhang has been a set of proposed Medicare local coverage determinations for iDose TR from five Medicare Administrative Contractors; management has indicated its 2027 outlook accounts for a range of potential outcomes. Despite that regulatory uncertainty, the market has rewarded Glaukos for its improving profitability and revenue trajectory.
Looking ahead, investors should monitor the trajectory of iDose TR adoption and the evolving Medicare coverage landscape, as proposed LCDs could influence reimbursement and utilization. Epioxa's commercial ramp, including payer access expansion and the planned 2027 launch of a keratoconus screening device, will be closely watched. The company's ability to maintain gross-margin expansion while scaling operating expenses toward a 2027 revenue target of $1 billion will be central to the valuation debate. Additional clinical milestones, including the iDose TRIO program targeting FDA approval by the end of 2027, and broader macroeconomic and healthcare-sector sentiment, round out the key factors investors should track. These are informational considerations, not financial advice. From what I see, the data on Tickeron’s AI Trend Prediction Engine helps put these drivers into broader context.
In my own research process, I often review Tickeron’s Trending AI Robots to identify active strategies across different risk profiles and timeframes. The page curates top-performing bots from hundreds available on the platform, covering equities and other instruments, which provides a practical starting point for evaluating systematic approaches without needing to sift through every option.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 252 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 34 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an ophthalmic medical device company
Industry MedicalNursingServices